| pubmed-article:20032845 | pubmed:abstractText | Currently the management of non-small cell lung cancer with first line chemotherapy is dependent on the histology. The growth of morbid anatomy laboratories and molecular biology, alongside the rapid expansion of new therapies, is necessary for the selection of patients according to predictive criteria of efficacy and tolerance, allowing definition of a made to measure treatment. | lld:pubmed |
